Overview
What is Childhood Arthritis And Rheumatology Research Alliance?
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is a collaborative nonprofit organization based in Washington, D.C. Their primary mission is to conduct research aimed at preventing, treating, and curing pediatric rheumatic diseases. CARRA members actively seek opportunities, establish a structure, and develop a scientific agenda to collaborate with potential funding sources, ultimately benefiting their patients. One of their key initiatives is the CARRA Registry, a database of children and young adults with various rheumatic conditions like juvenile idiopathic arthritis (JIA). This registry provides valuable data on various rheumatic diseases. The alliance works closely with the Duke Clinical Research Institute (DCRI) to launch the second phase of this registry.
Official website here: www.carragroup.org/
Is Childhood Arthritis And Rheumatology Research Alliance legitimate?
Childhood Arthritis And Rheumatology Research Alliance is a legitimate nonprofit organization registered as a 501(c)(3) entity. Childhood Arthritis And Rheumatology Research Alliance submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $260,822
Professional Fundraising Fees: $0
Other Salaries and Wages: $657,603
For more financial information, click here
Official website here: www.carragroup.org/
What is the mission statement of Childhood Arthritis And Rheumatology Research Alliance?
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) aims to collaborate with its members, potential funding sources, and establish a research alliance that benefits patients with pediatric rheumatic diseases. They actively develop a structure and scientific agenda, capitalizing on opportunities to conduct collaborative research aimed at preventing, treating, and curing these diseases. The organization's primary focus is on pediatric rheumatic diseases, such as juvenile idiopathic arthritis (JIA). CARRA collaborates with the Duke Clinical Research Institute (DCRI) to launch the second phase of the CARRA Registry, a registry of children and young adults with various rheumatic conditions, providing valuable disease and treatment data.
Official website here: www.carragroup.org/
Who is the CEO of Childhood Arthritis And Rheumatology Research Alliance?
Robert Colbert Md Phd is the President of Childhood Arthritis And Rheumatology Research Alliance.
Official website here: www.carragroup.org/
What is the revenue of Childhood Arthritis And Rheumatology Research Alliance?
Childhood Arthritis And Rheumatology Research Alliance's revenue in 2022 was $10,561,848.
Official website here: www.carragroup.org/
Who are the executives of Childhood Arthritis And Rheumatology Research Alliance and what are their salaries?
- Emily Von Scheven Md Mas (Past President) [Trustee/Director]
- Stacy Ardoin Md (Vice President) [Trustee/Director]
- Robert Colbert Md Phd (President) [Trustee/Director]
- Robert Fuhlbrigge Md Phd (Director)
- Jay Mehta Md Ms (Treasurer) [Trustee/Director]
- Christy Sandborg Md (Chair-Secretarty) [Trustee/Director]
- Carol Wallace Md (Director)
- Harry Saal Phd (Director)
- Leigh White Jd (Director)
- Daniel Solomon Md Phd (Director)
- John Sundy Md Phd (Director)
Official website here: www.carragroup.org/
Where can I find the form 990 for Childhood Arthritis And Rheumatology Research Alliance?
The Childhood Arthritis And Rheumatology Research Alliance’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.carragroup.org/
Learn more at the official website: www.carragroup.org/
Mission Statement of Childhood Arthritis And Rheumatology Research Alliance
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is a collaborative organization that aims to benefit patients suffering from pediatric rheumatic diseases. Members of CARRA actively seek opportunities, develop a structured plan, and collaborate with potential funding sources to establish a research alliance that can prevent, treat, and cure these conditions. CARRA's mission is to conduct collaborative research, capitalizing on the collective expertise and resources of its members to make significant strides in understanding and treating pediatric rheumatic diseases.
To achieve this mission, CARRA has launched the second phase of the CARRA Registry, a registry of children and young adults with pediatric-onset rheumatic conditions such as juvenile idiopathic arthritis (JIA). This registry serves as a cornerstone of CARRA, providing crucial disease and treatment data on a variety of rheumatic diseases. By pooling information from multiple sources, CARRA can identify trends, develop evidence-based treatments, and contribute to the overall understanding of pediatric rheumatic diseases. This collaborative approach allows CARRA to make significant strides in improving the lives of children and young adults living with these conditions, providing them with a brighter future.
Impact
This information is meant to be a general summary of Childhood Arthritis And Rheumatology Research Alliance. Please take the time to review official sources before making any decisions based upon the content provided here.
Saturday, July 20, 2024
Childhood Arthritis And Rheumatology Research Alliance, also known as CARRA, has made a significant impact in the field of pediatric rheumatology. Through collaborative efforts, CARRA members have worked together to capitalize on opportunities, actively develop a scientific agenda, and collaborate with potential funding sources to create a research alliance that benefits patients. One of the key initiatives of CARRA is the CARRA Registry, in collaboration with the Duke Clinical Research Institute, which serves as a valuable resource by providing disease and treatment data on children with pediatric-onset rheumatic conditions such as Juvenile Idiopathic Arthritis (JIA).
By conducting collaborative research, CARRA aims to prevent, treat, and ultimately cure pediatric rheumatic diseases. This dedication to advancing research in the field has led to improvements in the understanding and management of these conditions, ultimately improving the lives of young patients living with rheumatic diseases.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
RESEARCH STUDIES & COLLAB
Revenue
$9,696,363
MEMBERSHIP DUES
Revenue
$51,115
Organization Details
Founding Year
2014
Phone
(202) 772-1028
Principal Officer
Robert Colbert Md Phd
Main Address
1050 CONNECTICUT AVENUE NW 500, WASHINGTON, DC, 20036
Website
www.carragroup.org/
NTEE Category
Code: G51 - Disease
If you are a representative of Childhood Arthritis And Rheumatology Research Alliance and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.